Delivering DNA and RNA Vaccines
Where and How They Are Needed.
Orlance aims to deliver powdered, needle-free, shelf-stable, nucleic acid vaccines (DNA and/or RNA) with its epidermal vaccine delivery platform.
INTRODUCING ORLANCE MACH-1 ™
World Vaccine Congress Europe
from 11th to 14th October, 2022.
World Vaccine and Immunotherapy Congress West Coast
from 28th November to 1st December, 2022.
Orlance, Inc., headquartered in Seattle, WA, is developing its MACH-1® platform to deliver nucleic acid vaccines and related therapies without cold chain restrictions. Leveraging $9.6M in NIH SBIR funding, Orlance has developed the MACH-1 platform to intradermally deliver stable, powdered vaccines in a needle-free manner that minimizes dose size, eliminates cold chain requirements, and is poised to increase access and compliance. The company’s lead assets are at Pre-IND stage and poised for Phase 1 readiness in 2023.
CEO
25 years of bioengineering,
innovation development,
regulatory and clinical affairs,
product launch, VC and
executive experience.
CTO
Co-inventor of MACH-1
technology, formerly at
PowderJect, UW Professor, the
lab focuses on NA vaccines for
multiple pathogens.
Director R&D
15 years in NA
vaccine field, developed genetic
adjuvant platform at Profectus
Biosciences, Inc.
Manager
Preclinical Development Bioengineer,
Immunology, and nano delivery
system experience.
Mechanical Engineer
Medical device design and system
integration lead.
Senior Administrative and
Financial Manager
Experienced
biomedical research finance,
federal funding and
management professional.
Research Scientist and Analyst
Preclinical program laboratory
and business development
support.
